Enantioselective CYP inhibition by diclofop, the active metabolite of diclofop-methyl: Mechanism and relevance for human exposure

Key Points

• CYP inhibition by diclofop shows significant enantioselectivity, highlighting its potential pharmacological effects.
• The active metabolite of diclofop-methyl demonstrates distinct mechanisms affecting human health outcomes.
• Observational analysis reveals critical interactions between diclofop and CYP enzymes relevant to human exposure.
• Findings suggest that the relevance of enantioselective behavior warrants further safety evaluation regarding diclofop use.